Laevoroc Oncology Company Profile

Background

Laevoroc Oncology, established in 2019 and headquartered in Zug, Switzerland, is a privately-owned oncology development company. Founded by Dr. Thomas Mehrling and Dr. Davide Guggi, who collectively bring over 40 years of experience in oncology and the pharmaceutical industry, Laevoroc is dedicated to developing next-generation, game-changing cancer immunotherapies. The company's mission is to leverage state-of-the-art technology and extensive R&D experience to create a diversified portfolio of innovative cancer treatments, aiming to transform outcomes for patients with medically underserved hematological malignancies and other cancers.

Key Strategic Focus

Laevoroc employs an asset-centric business model, operating through three subsidiaries:

Laevoroc Immunology: Focuses on developing LR 09, a novel metabolic immune checkpoint inhibitor targeting leukemia relapse after allogeneic stem cell transplantation.

Laevoroc Chemotherapy: In partnership with Lipomed AG, this joint venture is advancing LR 06B, an oral gemcitabine prodrug designed for maintenance therapy in pancreatic, ovarian, and breast cancers.

Laevoroc Neuro-Oncology: Aims to build a pipeline of innovative drugs addressing brain cancers, including LR 02, a highly selective and potent ATR inhibitor with outstanding CNS penetration.

This structure allows each subsidiary to operate independently, facilitating tailored financing and licensing agreements, thereby enhancing the company's resilience and alignment with potential partners and patient needs.

Financials and Funding

In May 2021, Laevoroc Oncology successfully completed seed financing, raising over USD 1.1 million from private and individual investors. The company has been actively pursuing Series A financing to advance its subsidiaries' assets through clinical trials. In May 2025, Helix BioPharma Corp. acquired the oncology assets of Laevoroc Immunology AG and Laevoroc Chemotherapy AG for CHF 5.3 million, issuing 21,009,229 common shares as consideration.

Pipeline Development

Laevoroc's pipeline includes:

LR 09 (Ulodesine Hemiglutarate): A purine nucleoside phosphorylase (PNP) inhibitor developed for treating leukemia relapse after allogeneic stem cell transplantation. In February 2023, the FDA granted Orphan Drug Designation to LR 09, recognizing its potential to address significant unmet medical needs.

LR 06B: An oral gemcitabine prodrug combined with cedazuridine, designed to overcome the poor absorption of oral gemcitabine, achieving bioavailability comparable to its intravenous counterpart. This first-in-class, pre-IND candidate aims to expand treatment options for advanced cancers.

LR 02: A highly selective and potent ATR inhibitor with outstanding CNS penetration, targeting brain cancers. This innovative therapeutic principle is based on synthetic lethality, addressing the challenges associated with treating brain tumors.

Technological Platform and Innovation

Laevoroc's innovative approach includes:

LR 09: Functions as a metabolic immune checkpoint inhibitor, activating the immune system through cytokine release and expansion of germinal center B-cells and follicular helper T-cells. This mechanism aims to guide the immune system to eradicate relapsed leukemia post-transplantation.

LR 06B: A rationally designed oral prodrug of gemcitabine, releasing the active drug in the liver after first-pass metabolism. This design facilitates oral administration, reducing healthcare system and patient burdens, and enabling new uses of gemcitabine, including combination therapies with oral targeted agents.

LR 02: An ATR inhibitor with exceptional CNS penetration, introducing a novel therapeutic principle for brain cancer treatment based on synthetic lethality. This approach targets the vulnerabilities of brain tumors, aiming to improve survival rates.

Leadership Team

Dr. Thomas Mehrling, MD, PhD: CEO and Founder. A hematologist-oncologist and pharmacologist with over 20 years of experience in oncology drug development. Former CEO of Mundipharma EDO, he has a strong track record in building global oncology businesses.

Dr. Davide Guggi, PhD: CSO and Co-Founder. An entrepreneur and former head of a business unit at Mundipharma AT, with over 15 years of experience in oncology drug development. He is a CMC expert and Qualified Person (QP).

Dr. Shanta Bantia, PhD: CSO, Laevoroc Immunology. Founder and CEO of Nitor Therapeutics, with over 20 years of experience in the pharmaceutical industry.

Steve Engen, MBA: Business Development Strategic Advisor. An entrepreneur with over 20 years of experience in the biopharma industry and business development, focusing on East Asia.

Dr. Jessica Kourniakti, DPhil: COO, Laevoroc Oncology. Entrepreneur, owner, and CEO of Manage Mind AG, with over six years of experience leading operations and communications projects.

Leadership Changes

In May 2025, following the acquisition of Laevoroc's oncology assets by Helix BioPharma Corp., Dr. Thomas Mehrling was appointed as CEO and Director of Helix BioPharma. This strategic consolidation aims to strengthen Helix's portfolio and advance its mission to provide effective treatment options for hard-to-treat cancers.

Competitor Profile

Market Insights and Dynamics

The oncology therapeutics market is highly competitive, with numerous companies developing innovative treatments for various cancers. The market is characterized by rapid advancements in immunotherapies, targeted therapies, and personalized medicine, driven by significant unmet medical needs and the potential for substantial financial returns.

Competitor Analysis

Key competitors in the oncology therapeutics space include:

Novartis: A global healthcare company with a strong oncology portfolio, including targeted therapies and immunotherapies.

Roche: Known for its extensive cancer treatment pipeline, focusing on personalized healthcare and innovative diagnostics.

Bristol-Myers Squibb: A leader in immuno-oncology, developing checkpoint inhibitors and combination therapies.

Merck & Co.: Developer of pembrolizumab (Keytruda), a leading PD-1 inhibitor used in various cancers.

AstraZeneca: Focuses on oncology with a robust pipeline of targeted therapies and immunotherapies.

These companies have established market positions, extensive R&D capabilities, and significant financial resources, contributing to a competitive landscape in oncology therapeutics.

Strategic Collaborations and Partnerships

Laevoroc has engaged in significant collaborations to enhance its development capabilities:

Lipomed AG: In March 2022, Laevoroc Chemotherapy evolved into a joint venture with Lipomed AG to develop LR 06B, aiming to improve health equity and quality of care for cancer patients globally.

University of California, Los Angeles (UCLA): Collaborated on research identifying PNP as a novel metabolic immune checkpoint, supporting the development of LR 09.

Fred Hutchinson Cancer Center: Engaged in research collaborations to support the development of LR 09 for treating leukemia relapse after allogeneic stem cell transplantation.

Operational Insights

Laevoroc's asset-centric business model, operating through independent subsidiaries, allows for focused development and tailored financing strategies. This structure enhances resilience and aligns with the interests of potential partners and patients. The company's strategic collaborations and partnerships strengthen its market position and innovation capacity, enabling the advancement of its pipeline candidates through clinical development.

Strategic Opportunities and Future Directions

Following the acquisition of its oncology assets by Helix BioPharma Corp., Laevoroc's strategic roadmap includes:

Advancing Clinical Development: Progressing LR 09 and LR 06B through clinical trials to address significant unmet medical needs in oncology.

Expanding Collaborations: Leveraging existing partnerships and seeking new alliances to enhance research capabilities and accelerate development timelines.

Enhancing Market Position: Utilizing Helix BioPharma's resources and expertise to strengthen the market presence of Laevoroc's innovative therapies.

Pursuing Regulatory Approvals: Navigating the regulatory landscape to achieve approvals for pipeline candidates, facilitating market entry and commercialization.